Related Experiment Video
Updated: Jun 24, 2026
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
TFE3 Regulates Microglial Phagocytosis and Inflammation in MPTP-induced Parkinson's Disease
Qing Liu1,2,3, Wenmeng Xie4, Xiaofeng Tian5
1Postdoctoral Research Station in Biology, Hebei Medical University, Shijiazhuang, 050017, Hebei, China.
Abstract:
Parkinson's disease (PD) is a common neurodegenerative disease. Our previous single-cell sequencing results suggested that Transcription Factor E3 (TFE3) was only differentially expressed in microglia in the MPTP mouse model. However, the functional role of microglial TFE3 in PD pathogenesis remains unclear. First, motor function was assessed in MPTP mice following TFE3 overexpression in substantia nigra microglia. Second, RNA-seq was used to identify the function of TFE3 in microglia, and the molecular mechanism was verified both in vivo and in vitro. Finally, we investigated whether TFE3 nuclear translocation affects its transcriptional activity and subsequently influences microglia in vitro. Overexpression of TFE3 in substantia nigra microglia could alleviate PD-related phenotypes. RNA-seq revealed that TFE3 regulates microglial phagocytosis and inflammation. Mechanistically, TFE3 affects these functions by regulating the expression of Mer receptor tyrosine kinase (Mertk) and lysosomal-associated membrane protein 1 (Lamp1). Finally, Rapamycin could activate the nuclear translocation of TFE3 and enhance phagocytosis and alleviate inflammation of microglia. Our findings demonstrate that Rapamycin activates TFE3, which in turn upregulates the expression of Mertk and Lamp1 in the substantia nigra. This TFE3-mediated pathway plays a critical role in regulating microglial phagocytosis and inflammation in the PD model.
Insights
Transcription Factor E3 (TFE3) in microglia alleviates Parkinson's disease phenotypes by regulating phagocytosis and inflammation. Rapamycin enhances TFE3 activity, offering a potential therapeutic strategy for Parkinson's disease.
Area of Science:
- Neuroscience
- Immunology
- Molecular Biology
Background:
- Parkinson's disease (PD) is a prevalent neurodegenerative disorder.
- Previous studies indicated Transcription Factor E3 (TFE3) is differentially expressed in microglia within PD models.
- The specific function of microglial TFE3 in PD pathogenesis requires elucidation.
Purpose of the Study:
- To investigate the functional role of microglial TFE3 in Parkinson's disease.
- To explore the molecular mechanisms by which TFE3 influences microglial activity.
- To assess the therapeutic potential of modulating TFE3 activity in PD.
Main Methods:
- Assessment of motor function in MPTP-induced Parkinson's disease mouse models with TFE3 overexpression in microglia.
- RNA sequencing (RNA-seq) to identify TFE3-regulated genes and pathways in microglia.
- In vivo and in vitro validation of molecular mechanisms, including TFE3 nuclear translocation.
Main Results:
- Overexpression of TFE3 in substantia nigra microglia ameliorated PD-related motor deficits.
- RNA-seq identified TFE3 as a regulator of microglial phagocytosis and inflammatory responses.
- TFE3 was found to modulate the expression of Mer receptor tyrosine kinase (Mertk) and lysosomal-associated membrane protein 1 (Lamp1).
Conclusions:
- Rapamycin treatment promotes TFE3 nuclear translocation, enhancing microglial phagocytosis and reducing inflammation.
- The TFE3 pathway, by upregulating Mertk and Lamp1, plays a crucial role in regulating microglial function in Parkinson's disease.
- Targeting the TFE3-mediated pathway presents a promising therapeutic avenue for Parkinson's disease.
